Skip to main content
. 2022 Jun 16;2022:8714392. doi: 10.1155/2022/8714392

Table 5.

Comparison of incidence of cardiovascular adverse events in the nonmedicated group (case, %).

Group N Acute myocardial infarction Heart failure Cardiovascular death Revascularization Total occurrence
Administration group 1848 46 21 10 17 5.09 (94)
Nonmedicated group 273 11 8 3 4 9.52 (26)
Χ 2 8.774
P 0.003